ABBV | tickerfilter.com

Fundamental analysis

51%

Profitability 35%

Dept financing 33%

Liquidity 59%

Performance 70%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.04%

1 Month

-18.92%

3 Months

0.29%

6 Months

-9.80%

1 Year

3.25%

2 Year

8.92%

Key data

Stock price

$175.67

P/E Ratio

72.72

DAY RANGE

$172.32 - $188.39

EPS

$2.40

52 WEEK RANGE

$153.58 - $218.66

52 WEEK CHANGE

$3.93

MARKET CAP

311.087 B

YIELD

3.52%

SHARES OUTSTANDING

1.766 B

DIVIDEND

$1.55

EX-DIVIDEND DATE

04-15-2025

NEXT EARNINGS DATE

04-25-2025

BETA

0.06

PUBLIC FLOAT

AVERAGE 10 VOLUME

$10,624,145

AVERAGE 30 VOLUME

$8,186,341

Company detail

CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

ABBV - AbbVie Inc.